Ocumension Therapeutics (HKSE:01477) Days Sales Outstanding : 126.97 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Days Sales Outstanding?

Ocumension Therapeutics's average Accounts Receivable for the six months ended in Dec. 2023 was HK$108.6 Mil. Ocumension Therapeutics's Revenue for the six months ended in Dec. 2023 was HK$156.1 Mil. Hence, Ocumension Therapeutics's Days Sales Outstanding for the six months ended in Dec. 2023 was 126.97.

The historical rank and industry rank for Ocumension Therapeutics's Days Sales Outstanding or its related term are showing as below:

HKSE:01477' s Days Sales Outstanding Range Over the Past 10 Years
Min: 151.6 Med: 296.97 Max: 26141.61
Current: 151.6

During the past 6 years, Ocumension Therapeutics's highest Days Sales Outstanding was 26141.61. The lowest was 151.60. And the median was 296.97.

HKSE:01477's Days Sales Outstanding is ranked worse than
78.72% of 888 companies
in the Biotechnology industry
Industry Median: 72.34 vs HKSE:01477: 151.60

Ocumension Therapeutics's Days Sales Outstanding declined from Dec. 2022 (143.08) to Dec. 2023 (126.97).

Ocumension Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Ocumension Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Days Sales Outstanding Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

26,141.61

854.35

296.97

177.81

162.54

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial						297.43	169.16	143.08	172.49	126.97

Competitive Comparison of Ocumension Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Ocumension Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocumension Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's Days Sales Outstanding falls into.

Ocumension Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Ocumension Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (118.638	+	121.367)	/	2 )	/	269.471	*	365
=	120.0025					/	269.471	*	365
=	162.54

Ocumension Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (95.765	+	121.367)	/	2 )	/	156.051	*	365 / 2
=	108.566					/	156.051	*	365 / 2
=	126.97

Ocumension Therapeutics (HKSE:01477) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Ocumension Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Liu Ye	2101 Beneficial owner
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Chen Ziqing	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Boyu Capital Fund Iv, L.p	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines